Navigation Links
Common data determinants of recurrent cancer are broken, mislead researchers
Date:1/2/2013

In order to study the effectiveness or cost effectiveness of treatments for recurrent cancer, you first have to discover the patients in medical databases who have recurrent cancer. Generally studies do this with billing or treatment codes certain codes should identify who does and does not have recurrent cancer. A recent study published in the journal Medical Care shows that the commonly used data determinants of recurrent cancer may be misidentifying patients and potentially leading researchers astray.

"For example, a study might look in a database for all patients who had chemotherapy and then another round of chemotherapy more than six months after the first, imagining that a second round defines recurrent disease. Or a study might look in a database for all patients with a newly discovered secondary tumor, imagining that all patients with a secondary tumor have recurrent disease. Our study shows that both methods are leave substantial room for improvement," says Debra Ritzwoller, PhD, health economist at the Kaiser Permanente Colorado Institute for Health Research and investigator at the University of Colorado Cancer Center.

The study used two unique datasets derived from HMO/Cancer Research Network and CanCORS/Medicare to check if the widely used algorithms in fact discovered the patients with recurrent disease that the algorithms were designed to detect. They did not. For example, a newly diagnosed secondary cancer may not mark a recurrence but may instead be a new cancer entirely; a second, later round of chemotherapy may be needed for continuing control of the de novo cancer, and not to treat recurrence.

"Basically, these algorithms don't work for all cancer sites in many datasets commonly used for cancer research," says Ritzwoller.

For example, to discover recurrent prostate cancer, no combination of billing codes used in this large data set pointed with sensitivity and specificity to patients whom notes in the data showed had recurrent disease. The highest success of the widely used algorithms was predicting patients with recurrent lung, colorectal and breast cancer, with success rates only between 75 and 85 percent.

"We need to know who in these data sets has recurrent disease. Then we can do things like look at which treatments lead to which outcomes," Ritzwoller says. Matching patients to outcomes can help to decide who gets what treatment, and can help optimize costs in health care systems.

In a forthcoming paper, Ritzwoller and colleagues will suggest algorithms to replace these that have now proved inadequate.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Texting in College Classrooms Common, Distracting
2. Recovery from propofol anesthesia may be sped by use of common stimulant
3. Long-term neuropsychological impairment is common in acute lung injury survivors
4. Overuse Injuries Common Among Female College Athletes
5. Common Blood Pressure Drug Safe for Heart Failure: Study
6. Test links strains of common parasite to severe illness in US newborns
7. Common Plastics Chemical Might Boost Diabetes Risk
8. Off-Label Drug Use Appears Common
9. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
10. Slow-growing babies more likely in normal-weight women; Less common in obese pregnancies
11. Common Blood Pressure Drugs May Not Cut Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix ... of Emergency Medicine , an emergency medicine professional association, to support the organization's ... , The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Emergency rooms provide ... to find. Unfortunately, this can leave patients with dental emergencies at risk of losing ... now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... , ... Armune BioScience signed a definitive agreement with ARCpoint ... across the country. Launched in April of 2015, Apifiny is the only cancer specific, ... order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... LONDON , February 10, 2016 A new report ... 2021 - states that the Alzheimer,s disease market will more than double ... 2021, at a Compound Annual Growth Rate (CAGR) of 11%. ... Italy , Spain , the UK, and ... prevalence during the forecast period. --> Canada , ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... viral gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical ... and other chronic diseases, have entered into a Manufacturing ... produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in ... --> This relationship will leverage Lonza,s ...
(Date:2/10/2016)... , Feb. 10, 2016 Immune Pharmaceuticals Inc. ... announced today that it has filed a patent application ... other cancers. --> --> ... by administration of Ceplene (histamine dihydrochloride) in combination with ... of predicting the efficacy of Ceplene and IL-2 therapy ...
Breaking Medicine Technology: